iHear pairs with FSA.com on FDA-cleared home hearing screener
iHear Medical on Wednesday announced that it has partnered with FSAstore.com to offer the iHearTest, the first and only FDA-cleared home hearing screener, with reimbursement eligibility through flexible spending account programs. Offering FSA reimbursement eligibility furthers iHEAR’s mission to provide consumers with affordable and accessible hearing solutions.
The FDA-cleared iHearTest has been clinically proven to accurately score hearing ability in each ear on a scale from 1 to 5 based on World Health Organization guidelines. Anyone who suspects that they or a loved one is experiencing hearing loss can now purchase the iHearTest and reimburse the cost through their FSA program. Results of the iHearTest can be used to program iHEAR hearing devices, including the iHEAR HD and iHEAR MAX, based on a consumer’s individual needs.
“We are excited that the iHearTest is now offered at FSAstore.com,” Adnan Shennib, iHear Medical president, said. “For people living with hearing loss, the availability of the iHearTest at this leading online retail outlet will offer additional access to our breakthrough hearing screening technology.”
Hearing aids became available over-the-counter thanks to new legislation signed last fall, and iHear was one of the pioneers in the space with a retail option at the ready.
Consumers may become particularly interested in OTC hearing aids toward the end of the calendar year as they look to empty their FSA accounts, Jeremy Miller, CEO of FSA.com, recently shared with Drug Store News in an exclusive interview last year.
GNC weighs in with new diet aid supplement
GNC this month introduced an innovative range of supplements aimed at the large, fast-growing weight management category.
“Our vertically integrated model and R&D strength gives us the unique ability to anticipate and understand consumer needs and pioneer new products and formulas,” Ken Martindale, GNC CEO, said. “That’s a tremendous competitive advantage and a pillar of our strategy. As we continue to develop new and innovative offerings, we believe we can drive differentiation and profitable growth.”
The addition of Slimvance extends GNC’s leadership position in the $6.1 billion weight management market, which is expected to grow at a compound annual growth rate of more than 4% through 2020. The company believes Slimvance has the power to attract new customers, build basket size and deliver incremental sales growth, and plans to add new products to the line during 2018.
The company’s new Slimvance Core Slimming Complex is an all-natural, non-stimulant weight management botanical blend. Consumers’ initial response to the product has been strong, the retailer stated. And it further differentiates its shop from the competition.
“This company was built on giving consumer products and solutions that they can’t get anywhere else, on pioneering new formulas and new ideas and on anticipating customer needs,” Martindale told investors during his first conference call last year. “In this shifting retail climate, it’s a legacy strength that we can leverage.”
Martindale joined the specialty supplement retailer from Rite Aid in September.
The product line is available in stores, online and in the company’s Amazon Marketplace. GNC is supporting the launch with a multi-channel marketing strategy that includes a direct-to-consumer campaign, social media, digital video, display and a dedicated site where customers can purchase Slimvance with a single click.
Blue Emu generates awareness with Arthritis Foundation
The Arthritis Foundation partnered with Blue Emu Maximum Arthritis Pain Relief Cream, NFI Consumer Products announced Monday.
“Since the launch of our Blue Emu Maximum Arthritis SKU, we have received many letters praising the help this product provides to customers with Arthritis,” Benjamin Blessing, executive vice president sales and marketing for the Bristol, Tenn.-based company, said. “It just made sense that we partner with the Arthritis Foundation so we could help raise awareness for the pain many of our Blue Emu Maximum Arthritis customers deal with every day.”
The partnership continues through 2018 and features a specially marked Blue Emu Maximum Arthritis tube with the Arthritis Foundation logo. By partnering with the Arthritis Foundation, Blue Emu will help raise awareness about arthritis and support the Arthritis Foundation’s mission to help the more than 54 million Americans chart a winning course and make each day another stride towards a cure.
“At the Arthritis Foundation, we’re committed to helping people with arthritis live their best life, which includes managing and relieving their pain,” Ann McNamara, the Arthritis Foundation senior vice president of revenue strategy, said. “This new partnership with Blue Emu underscores our belief that people with arthritis should have a variety of treatment options when deciding how they control their pain.”
Blue Emu will ship the specially marked Maximum Arthritis product beginning in February 2018. The product is the No. 5 branded external analgesic, according to the latest IRI sales data, and it’s growing fast. Sales for the 52 weeks ended Dec. 3 totaled $42 million across total U.S. multi-outlets, representing growth of 22.3% . That outpaces growth of 17.8% for the entire category, which reached $723.6 million in sales in that period.
And that growth is coming from a premium pain relief SKU. Blue Emu sells at a 2.3 x premium to the average pricepoint of $6.71 for the category with an average price per unit sold of $15.38. NFI sold 2.7 million units in the same period noted above, representing growth of 22.2%.